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Statement of Disclaimer
Since this project is a result of a class assignment, it has been graded and accepted as fulfillment of the course
requirements. Acceptance does not imply technical accuracy or reliability. Any use of information in this report is done
at the risk of the user. These risks may include catastrophic failure of the device or infringement of patent or copyright
laws. California Polytechnic State University at San Luis Obispo and its staff cannot be held liable for any use or misuse
of the project.
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ABSTRACT
First responders need a quick, sterile, and convenient way to sample blood for glucose testing because glucose levels are
a vital metric in assessing time-critical emergency situations. The blood sampling process consists of pre-sterilizing the
sample site on the skin with an alcohol pad, pricking the skin with a lancet, and lastly, after sampling, putting a bandage
over the prick site. The scope of this project is to design a device which integrates and streamlines the use of the three
sub-processes (sterilization, lancing, and bandaging) while upholding the necessary requirements of a single-use medical
device and considering other factors which could make the device marketable in future production/use. Our solution
focused on the integration of the subprocesses with the main goal of reducing the inefficiencies in the current
procedure, which mainly come from the time it takes for a first responder to secure the materials needed for each step
and administer the care. Our final design was effective in meeting our main goal, leading to a 70% improvement in time
to complete the process. This document outlines the background, research, project management, concept formulation,
as well as the final design, detailed drawings, manufacturing, and testing of the project.
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1 INTRODUCTION
First responders must respond to emergency situations and determine the source of a life-threatening problem before it
is too late. Every second counts, and one of the most common procedures administered to non-responsive patients is a
glucose test. The methods currently used to accomplish this process involves multiple components and packaging that
can be difficult and time-consuming to use in the field. Engineering optimization can improve the speed and ease this
process by creating a new product that incorporates all the process components into one package.
Tim Nurge, a local paramedic, and former Cal Poly employee identified this design opportunity while observing the
current process for taking glucose levels, especially in emergency situations. He has requested that we design a device
that can reduce the time needed to sample blood for glucose testing.
The purpose of this project is to develop a new product that reduces the time to perform a glucose test for first
responders, as well as make it easy to accomplish on oneself for at home users. This product design must comply with
current FDA (Food and Drug Administration) regulatory laws, including sterilization requirements, sharps controls, and
the restriction that this product will be a single-use medical device.
We are a team of mechanical engineering students at California Polytechnic State University, in San Luis Obispo, and
undertook this project as our senior design project. This document is an overview of our entire design process.
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2 BACKGROUND
Our sponsor and other first responders need a way to more efficiently measure a patient’s blood glucose. Blood glucose
level is a metric used to help diagnose a patient during an emergency, specifically helping determine whether a patient is
experiencing a stroke. According to the National Institute of Neurological Disorders and Stroke, the most important
test in emergency stroke evaluation is glucose (or blood sugar), because levels of blood glucose which are too high or
too low can cause symptoms which may be mistaken for stroke. These two conditions have vastly different treatment
methods, so it is important to determine the patient’s condition as quickly as possible to move forward with the correct
treatment in such a time-critical scenario.
In order to measure the blood glucose levels of a patient, a blood sample must be taken and processed with a handheld
electronic glucometer, which provides the glucose reading. The process of collecting this blood sample used for the
glucometer is the focus of our project.
The current process of taking a blood sample at the scene of an emergency requires a first responder to follow the
following steps: First, the patient’s skin must be sterilized using an isopropyl alcohol wipe. The alcohol wipe must be
opened by tearing the package, removing the wipe, and applying the wipe to the fingertip. Second, a lancet is used to
prick the finger and draw blood. A visual example of how a lancet is applied to the fingertip is shown below in Figure 1.
This blood sample gets used with a glucometer to take the reading. Third, a bandage is used to cover up the site where
blood is drawn to prevent exposure.

Figure 1: Typical application of a blood lancet to draw a blood sample on a patient’s fingertip [1].
11

During this process, simple tasks such as opening the wipe or unwrapping the band aid can take an unnecessary amount
of time, especially because emergency responders must wear gloves during this process which make it difficult to do the
tasks efficiently.
Our goal is to improve the process in as many ways as possible, but the team's main objective is cutting down the time
of use to between 20 and 25 seconds, and to bring the number of steps required to complete the process down to four
(while there are three main “steps” of the procedure that were defined earlier as necessary to perform the blood
drawing, each of these main steps has their own series of independent steps associated with them, and we identified 6
total independent steps necessary in the current process). The current process, as Tim described, takes roughly a
minute, where much of the extra time consumed comes from having to handle three separate products, as well as
opening the packaging for each of the components in between steps. While first responders typically keep their supplies
together in a bag, similar to the one shown in Figure 2 below, it still requires them to interact and deal with each of
them separately. In order to streamline this process, a 3-in-1 device which allows easy access to the wipe/bandage for
applying and has the capability to be used as a lancet, can help save the time lost from interacting with the 3 different
supplies on their own.

Figure 2: Example of a glucometer bag with lancet supplies inside. [2]
A secondary goal is to make the 3-in-1 lancet appealing to at-home diabetics so that the device is marketable within
their customer base as well. This is what drives the incorporation of easy self-use into the design, so that it is much
more convenient to perform when others are unavailable to assist.
Because this product will be classified as a commercial medical device, there are many regulations which must be
adhered to in order to bring it to the market. Specifically, the U.S. Food and Drug Administration has many
requirements in place for a medical device to be clinically tested or sold. Eventually, our final product would be massproduced, and sold to both paramedics and general consumers including at-home diabetics.
In order to get more insight as to what parts of the blood drawing process work well and which does not, a survey was
sent to our sponsor’s co-workers (EMTs, CNAs, and nurses) to collect data on the current process and to gather ideas.
Results from the survey gave us more information regarding what step takes the longest in the process, how long it
typically takes, where improvement should be focused, how often tests are being performed, and the success rate of the
typical lancet. Our most critical finding from the survey is that the current process took an average time to complete of
about 60 seconds. This metric was used when outlining our design goals for the device.
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2.1 FDA DEVICE CLASSSIFCIATION RESEARCH
This product contains the function of three medical devices, so we performed research on blood lancets, alcohol pads,
and bandages to determine design and FDA submission/approval requirements. Medical device classifications
determine the level of regulatory control in order to ensure device safety and efficacy. This defines the premarket
submissions and demonstrations of compliance to the FDA required for product launch.
There are three medical device classifications; class 1, 2, and 3. Class 1 devices require general controls. Class 2 devices
require general controls and special controls that might vary on the specific device group. Last, class 3 devices require
general controls and a premarket approval. The complexity of premarket steps increases as each classification increases
with number [3].
From our research of the FDA database, bandages are classified as a class 1 device. There are 3 types of bandages:
adhesive tape [4], liquid [5], and elastic bandages [6] and all are classified as class 1. Alcohol pads are enumerated as
unclassified devices [7], but with further investigation, alcohol pads are exempt from premarket notification
requirements under an FDA guidance posted in 2019 [8]. Lastly, lancets are currently classified as a class 1 device [9].
With two devices being class 1, and one being exempt, we predicted the need to only satisfy general controls set by the
FDA to stay within compliance. One interesting detail, and possible problem to arrive in the future is the potential
changes to the device classification of “safety” type lancets from class 1 to class 2 [10]. This would add more controls
and make the devices subject to premarket review. If this proposal were to come to fruition and change the
classification of lancets, then the approval process would become much more difficult to accomplish. This proposal
gives incentive to complete product design and premarket submissions relatively soon to take advantage of the easier
approval process and leverage a possible barrier to entry for future competitors in upcoming years.
2.2 FDA CLASSIFICATION STRATEGY:
To aid in our FDA research, we consulted individuals that have experience in medical device validation and medical
device start-ups. Our goal was to confirm that our scope of design was feasible from a validation perspective. We first
talked with Dr. Crockett from the dean’s office at Cal Poly. He raised some concerns, specifically the possibility that
incorporating multiple class 1 devices into a new device could mean the device is novel enough to be a class 2 device.
With this concern that could make certain designs unfeasible, we reached out to Alan Curtis, an FDA consultant that
had more precise knowledge on specific FDA policies. From our meetings with Alan, we were able to arrive at an
acceptable FDA strategy. We can validate the product as a kit and separately validate each component as class 1 devices
separately. This creates more validation work than desired, but far less the time and capital required to validate a class 2
device. We determined this strategy the best course of action moving forward with our design ideation, making sure to
keep our functions separate enough to be assembled as a “kit” in the last stage of manufacturing. [11] This allows us to
create a novel device by making only subtle design changes and obstacles.
2.3 OSHA DEVICE TYPE REQUIRMENTS
OSHA (Occupational Safety and Health Administration) codes define required workplace conditions requirements of
supplied tools to employees. We researched OSHA guidelines for hospitals and paramedics to define requirements our
device must satisfy so these entities can purchase the device and stay in compliance with OSHA. We found that
OSHA’s bloodborne pathogens standard requires “safety” type lancets be supplied by employers for employee use [12].
Although a lot of paramedics are government employees and OSHA requirements can vary depending on individual
state plans, [13] state plans that do not follow this OSHA requirement should not be the product target. In order to sell
this product to all 50 states, we had to develop the lancet subassembly as a “safety” type lancet. Safety type lancets are
developed to minimize accidental pricks to the user by encasing the needle in a shielding mechanism. This mechanism
usually also contains a method of deploying the needle with a controlled action from the user. This requirement was
taken into consideration during the ideation portion of our design process.
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2.4 EXISTING AND RELATED PRODUCTS
A large consideration for our design was working around existing patents for blood drawing lancets, for example, #1 in
the Relevant Patent Findings (Table 1) below. This is the type of medical lancet that our sponsor uses in the field in his
profession as an EMT.
Other existing patents listed in Table 1 below were helpful during the ideation stage of the project, to be mindful of the
existing patents filed for this unique application. It is important to have a unique design in order to create a product that
is patentable, so our designs were required to work around the other technologies.
Patent Number

1. US10842428B2

Table 1. Relevant Patent Findings
Patent Title
Drawing
Contact activated lancet
device

2. US8333715B1

Blood glucose sampling wheel

3. KR101047289B1

Lancing device with trigger
mechanism for penetration
depth control

4. JPWO2003084401A1 Lancing device for one skin
puncture

5. US20180160957A1

Blood lancet with hygienic tip
protection

6. US6875223B2

Twist off lancet needle
bearing cartridge

7. US6432120B1

Adjustable needle depth
lancet
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3 OBJECTIVES
3.1 PROBLEM STATEMENT
First responders and diabetics need a quick, sterile, and convenient way to sample blood for glucose testing because
glucose levels are an instrumental vital metric in managing daily blood sugar and assessing emergency situations.
The boundary diagram as seen in Figure 3 is a visual representation of the scope of work of the project. The dotted
blue lines, denoting our system, indicate which elements of the product process we have control over.

Figure 3. Boundary diagram illustrating the scope of the project.
On the righthand side within our system outline are the three primary instruments that this project concerns. In step 1,
the isopropyl alcohol is applied to the finger, and in step 2, the lancet draws the patients’ blood. Step 3 involves putting
the blood onto the test strip, but as shown in the diagram, this part of the process does not concern our design. Lastly,
in step 4, the finger is bandaged up.
Each of these three processes (sterilizer, lancet, bandage) are targeted within our scope and were designed individually
and with respect to all the other components. The three processes were optimized for efficiency while maintaining
sterility. Also inside our system is the presence of germs, which is the indicator that sterility would be a challenge in this
project. We were required to uphold to medical standards, meaning we must keep the process as sterile as possible.
3.2 DESIGN CONSIDERATIONS
Table 2 displays a list of wants and needs to be met by our product. The wants and needs are sorted from most
important to least important.
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Table 2. Summary of Wants and Needs
Needs
Sterility
Disposability
Blood Draw Efficacy
Bandage Application Efficacy
Alcohol Wipe Efficacy

Wants
Quickness of Use
Purchase Cost
Packing Efficiency
Intuitive Use
Ergonomics
Simplicity
Size
Easy to Use (One Hand)
Minimal Pain Induced from Use

CUSTOMER NEEDS
Our customer needs are metrics we determined were critical for design functionality. These took the highest priority for
the evaluation of our design choices.
• Sterility: Our device is planned to be sold as a commercial medical device; Therefore, we must follow the
sterility regulations put in place by the FDA for the lancet, bandage, and alcohol pad portions of the design.
Ensuring sterility compliance in our design is a necessity, even if it comes at the cost of impeding other design
objectives for the product.
• Disposability (Sharps control): Our device is intended to be used by emergency responders in the field and by
medical professionals in healthcare establishments. In order to be used in these settings, our device (which
inherently has a hazard/risk associated by including a sharp object) must be safely disposable with no sharp
edges exposed after use.
• Blood drawing efficacy: In order to have a functional and therefore marketable product, our lancet must be able
to draw blood at a reasonably consistent success rate.
• Bandage application efficacy: Our device must be able to successfully apply a bandage to the site where blood
has been drawn.
• Alcohol wipe efficacy: Our device must be able to successfully clean the skin surface which blood will be drawn.
CUSTOMER WANTS
Our customer wants are metrics that are important to making a good design. They are not as critical as customer needs,
but were considered when evaluating design choices to satisfy customer needs.
• Quickness of use: The primary reason our sponsor decided to undertake this project is that the current method
of drawing blood could be sped up in emergency situations with a better process. Our design will work to
streamline the process of drawing blood for glucose monitoring by reducing time taken to complete the
following steps: sanitizing the finger, pricking the finger, and bandaging the finger.
• Purchase cost: An integral part of our project scope, our design will have to compete with the current process’s
cost, in order to be considered to widely replace the current process.
• Packing efficiency: Commonly, the necessary materials to complete the blood drawing process are stored inside
a small bag with the glucometer for easy access. Our design should allow first responders to have quick access
to the devices, and to accomplish this, they must be able to be efficiently packed into a glucometer bag.
• Intuitive use: We want to ensure that the product requires little to no extra training to use, so that even in highstress emergency situations, it is extremely clear to the operator how to operate the device. This will help
eliminate the risk of misuse in the field, which could disrupt the process being completed by first responders.
• Ergonomics: Making the product comfortable to hold and operate can decrease time for use and help prevent
accidental misuse, as well as improving overall user satisfaction.
• Simplicity: Reducing the number of steps required to operate the device can potentially speed the procedure and
reduce material costs.
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•
•

•

Size: Reducing the size of the device can increase packing efficiency and reduce cost.
Ease of use (one hand): This customer want is focused towards the at-home diabetic. When using the device on
oneself, it can be difficult to sterilize, prick and bandage with one hand (since blood is being drawn from the
other hand). When the site which blood will be drawn from is improperly sterilized, it introduces a health risk
which can result in infections.
Pain induced from use: Ideally, pricking the finger will not have a drastic increase in pain levels during use
compared to the current process.

3.3 QUALITY FUNCTION DEPLOYMENT
Listed in Appendix A, the House of Quality document served as a process to visually list our customer base, their needs
and wants, and what benchmarks and specifications to use to quantify those wants and needs. The listed specifications,
shown in the top row of the QFD, served as guides for what we wanted the product to achieve and were assessed
during the testing stage of our project. These were derived from our customer requirements which were created with
the user’s experience of the end product in mind. The QFD determined the metrics for which evaluate our design and
were referenced when evaluating conceptual designs.
3.4 SPECIFICATIONS TABLE
Shown in Table 3 are the specifications for the product found from the House of Quality. Each specification addresses
a necessary, measurable target for the 3-in-1 lancet. The sterility must meet the protocol for pathogen presences, in
ppm. The time of use is simply the time it takes someone to use the product. This includes using the alcohol wipe, the
lancet, and the band-aid. The target is to get the entire process to take a maximum of 20-25 seconds. This is directly
related to the next specification, which is number of steps. The goal is to get the entire process able to be completed in
4 steps or less. The cost to manufacture the entire product should be at most $2.00. The reason we are shooting for
such a low price is due to the fact that buying the three products we would need to combine into the 3-in-1 lancet, are
relatively cheap when bought in bulk. The size specification was decided to be no bigger than three cubic inches, but
what needs to be considered is the overall shape. It is important to have the device be made in a way that it can be
conveniently stacked with several other lancets to be able to carry many at a time. The blood drawing efficacy, or rate at
which the device needs to successfully draw the patient's blood is set at a 90% success rate. Sharps control, or the
maintenance of harmful objects in a healthcare environment, needs to satisfy FDA regulations.
The high-risk specifications, sterility and sharps control are high risk because they involve potential harm to patients.
These specifications need to be maintained carefully in order to ensure a product that is safe for its customers.
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Spec #

Specification Description

1

Sterility

2
3
4
5
6
7

Time of use
Number of Steps
Cost/unit
Size
Blood Draw Efficacy
Packing Efficiency (Amount
fit in glucometer bag)
Sharps Control
Input force to deploy lancet
Pain rating comparison

8
9
10
11
12

Learning curve / Intuitive
use
Meets user goals w/ survey

Table 3. Engineering Specifications Table
Requirement or Target
Tolerance
(units)
Meets protocol for
Y/N
pathogen presences
(ppm)
20 – 25 (seconds)
Max
4 (steps)
Max
2.00 ($)
Max
3 (in3)
Max
90 (%)
Min
6 (devices)
Min

Risk

Compliance

H

A

M
M
L
L
M
M

T
A
A
I
T
I

Satisfies FDA regulations
<1 (lbf)
<2 higher than current
(points)
Learn in 30 (s)

Y/N
Max
Max

H
L
L

T
T
T

Max

L

T

Meets goals

Y/N

M

T

* Risk of meeting specifications: (H) High, (M) Medium, (L) Low
** Compliance Methods: (A) Analysis, (I) Inspection, (S) Similar to Existing, (T) Test
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4 CONCEPT DESIGN
The concept ideation process consisted of performing a functional decomposition of the blood glucose lancing process,
creating function prototypes, evaluating methods for each sub function using Pugh matrices, and finally, weighing the
options in a weighted decision matrix to select the product’s final preliminary design choices. The final product
concept, shown in Figure 4, consists of: a round bandage, standard linear actuated lance, and a tear off sterilizer pad all
attached on a “rocket ship” inspired platform that sheds its layers as the process goes on.

Lancet Cap
(w/ Alcohol Pad)

Lancet Body

Bandage /
Bandage Mount

Figure 4. Preliminary Design Isometric View
4.1 CONCEPT DEVELOPMENT AND FUNCTION CONCEPT PROTOTYPES
To begin developing concept ideas for our 3 in 1 medical lancet we applied the functional decomposition process. The
functional decomposition process involves taking our overall device function and breaking it into its smaller constituent
parts. This process allowed us to visualize the different aspects of our device in a way that was conducive to generating
new ideas. The blood glucose lancing process was divided into its main sub functions and the next levels of the sub
functions were thought of until the functions could not be broken down any further.

Figure 5. Functional Decomposition Function Tree.
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The functional decomposition process allowed the important sub functions to become clear, and these functions were
taken to the next step of brainstorming. The team deemed the four following sub functions as pertinent to the overall
function of our product: cleaning the finger, poking the finger, covering the finger, and keeping all the elements
together. These functions were defined based on the current products which are commonly used in the field, and the
individual steps which are necessary to compete the blood drawing process.
The first function, Clean Finger, is where the user cleans and prepares the surface of the skin where blood will be
drawn. Currently this is performed through the use of an alcohol pad, and our main objectives for this function are to
thoroughly sanitize the skin and to ensure that the packaging of the sanitizing device is easy to open and use.
The second function is Prick Finger, where the user draws blood from the patient by using a medical lancet. Our top
priorities for this function are to design a lancet which keeps the user safe from accidental punctures, to maintain the
sterility of the puncture needle, and to ensure our lancet meets a minimum efficacy requirement.
The third function is Cover Finger, where the user bandages the site where blood had been drawn. Our goals for this
function are to make our bandage easier to use than the industry standard, and to allow for one handed use.
The fourth function is Keep Together, which encompasses how the device will integrate all three of the previous
functions into one unit. The goals of this function are to integrate the components in such a way that the device as
compact as possible, and to present the functions to the user in a way that is clear and easy to understand. We deemed
this its own individual function because our three procedural functions are all independent of each other, and so the
integration of them was designed with ergonomic considerations as the main priority, and individual function
integration would be considered after our main strategy for use was already outlined by the fourth function.
The team used brainwriting to brainstorm new concept ideas for each function. Brainwriting involves each team
member being free to write down any idea without limits. For each individual function, each team member wrote,
sketched, built upon and described any idea they could think of for that specific function. This allowed the team to
generate numerous concept ideas, which were taken to the next step of ideation and idea selection.
Our team created function prototypes based on the results of our brainwriting. Each team member created 5 simple
models using foam board, cardboard and play-doh that represented ideas taken from the brainwriting process. These
models furthered the process of idea generation by adding the physical sense to the process. The models helped the
team better understand the manufacturability, size, and basic physical functionality of our product and its ideas up to
that point.
4.2 PUGH MATRCIES
After generating multiple design concepts for each function, we used Pugh matrices to evaluate the effectiveness and
feasibility of each potential idea, and to narrow down our design options. Using criteria from our house of quality, we
began with a wide range of ideas for each function and compared them to a baseline for that specific function. Doing
so allowed us to score each idea as performing better or worse than the baseline for each criterion, and the total
difference across each idea being scored better or worse was used to determine which ideas were an improvement to
the baseline, and by how much. From these Pugh matrices, which are included in Appendix C, we found top function
designs for each category.
The results of the Pugh matrices were taken to our project sponsor, and he helped evaluate each idea for feasibility and
effectiveness from a customer perspective.
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4.2.1 CLEAN FINGER PUGH MATRIX
For the clean finger function, the Pugh matrix showed that several ideas had similar potential to improve upon the
baseline design. Some ideas were ruled out based on determination that they would not be an improvement compared
to the baseline (evident by a result equating to 0 or less). While there was no large spread in scoring results, the matrix
resulted in 5-6 top ideas, which would be used later in our individual function weighted decision matrices. The top 3 by
raw score are shown in the next figures.
Shown in Figure 6, the tear-away strip with the pad attached to the length of the strip would allow the user to open the
packaging (closely resembling the current industry standard) and have the pad ready in-hand after opening, without
having to reach into the pouch after it is opened to remove the pad by hand, improving speed and reducing step count.

Figure 6. Tear-away strip with pad attached along length.
Similar to the tear-away strip, shown in Figure 7 is the tear-away panel with the pad attached to the panel surface. This
also allows the user to have the pad ready-in hand after opening, except the panel provides a different method of
opening and offers different ergonomics compared to the commonly used ripping motion used to open these packets.

Figure 7. Tear-away panel with pad attached to panel surface.
Next, show in Figure 8 the removable cap with the pad attached to the cap reduces the step count even further than the
tear-away packaging, and allows the design to be more condensed and ergonomic to use.

Figure 8. Removable cap with pad attached to cap.
4.2.2 PRICK FINGER PUGH MATRIX
Six different methods of taking the patients’ blood were evaluated in a Pugh matrix. The full results can be found in
Appendix C. The results from the “Prick Finger” Pugh Matrix revealed the top 3 methods of taking blood from the
patient. The top 3 methods were deemed: the standard medical lancet (Figure 9), a torsional spring method (Figure 10),
and a side clicking methodology (Figure 11).
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Figure 9. Standard Medical Lancet. [12]
The standard medical lancet is considered the gold standard in the industry, and it is already FDA approved for safety
and sterility.

Figure 10. Torsional Spring Lancet.
The torsional spring method of pricking the patients finger involves a torsions spring, rather than a linear spring. This
method is both easy to use and safe, as the housing of the lance and spring is well encased in the body of the device.

Figure 11. Side Click Lancet.
The side click lancet involves pressing a button on the side of the lancet to engage the lance. This method allows for
quick use and is the most ergonomic of the options.
4.2.3 COVER FINGER PUGH MATRIX
The Pugh matrix for the prick finger function consisted of 5 different methods; a circular band-aid adhered to the body
of the device, liquid skin, medical tape, medical glue, and a regular band-aid with large tabs. The matrix with sketches of
each method can be found in Appendix C. The highest-scoring methods were the medical tape, the circular band-aid,
and the band-aid with large tabs. Ideas from each of these methods can easily be combined with each other in a way
that results in the final design having the best parts of each method. Having large tabs offers a way to easily open the
band-aid quickly and efficiently. The final method used for the cover finger function is somewhat dependent on the
design of the overall device.
The circular band aid shown in Figure 12 is very simple and would not be difficult to incorporate into the final design
since it is so small, adding in the idea of large tabs would make this method fit the design goals better.

Figure 12. Circular band aid. [22]
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The medical tape method, Figure 13, was one of the highest scoring methods in the Pugh matrix. It is extremely simple
and would offer quickness and ease of use to the design.

Figure 13. Medical tape. [23]
Both of these methods to cover the finger prick have good qualities that could satisfy the customer’s original wants and
needs, but there are issues that arise with these two methods in the aspect of how they will be incorporated into the
final design. A liquid glue-type bandage could be the right thing to use in an application like this. Examples of liquid
glue are shown below in Figure 14.

Figure 14. Medical glue and liquid skin. [24]
4.2.4 KEEP TOGETHER PUGH MATRIX
The results from the Pugh Matrix reveals 3 top geometric design ideas for arranging the system components together.
These top 3 were “Semi Circle”, “Squeeze Sides”, and “thin paper-centric.” This single function has some dependance
on the previous 3 steps as some choices made for step-component designs might fit better in a specific geometry.
Therefore, these concepts were evaluated specifically on their merit as a housing. Sketches and further descriptions are
below.
Shown in Figure 15, the semi-circle design changes the traditional shape of the lance housing to a circular shape where
the band-aid is wrapped around the curved side. The lance deployment site and alcohol prep is on the flat side of the
shape. The users hand grips over the tape side to lance then turns the device around to peel the band aid off for
application.
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Figure 15. Semi-Circle.
The squeeze sides design, Figure 16, makes use of a container on either side of the lance housing for the bandaging and
alcohol prep. This design can open all 2 containers with one cap on the top which adds simplicity to the process.
Although the side containers can be flexible to hold fluid for prep and bandaging, they can also be used as dispensers to
grab each out the opening depending on the function.

Figure 16. Squeeze Sides.
The thin paper-centric design, Figure 17, primarily makes use of traditional packaging methods and design for the
alcohol prep and bandage with easy open tabs on either side with color coded number for easy identification. The lance
is in a thin plastic housing that runs the length of the band aid.

Figure 17. Thin Paper-Centric.
4.3 WEIGHTED DECISION MATRICES FOR CONCEPT DESIGN DECISION
We determined that all of our project’s functions were independent of each other since they each encompassed
different discrete steps of the process. We decided the best method of design refinement would be making weighted
decision matrices for each function created. A weighted decision matrix compares alternative designs with respect to
relative criteria. The best system level design was determined based on the findings of our matrices. We evaluated more
choices than those that performed well in the pugh matrices to keep more flexible in our design choices. This flexibility
also worked well for us because at this time, we were waiting for survey results tell us more specific and reliable metrics
on desirable design traits. We cross checked our function evaluation results by getting input from our project sponsor
and paramedic, Tim Nurge. Taking this review into account supplemented the costumer perspective we have not yet
acquired from our survey since it is still in IRB approval, which is the Cal Poly Institutional Review Board.
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4.3.1 CLEAN FINGER DECISION MATRIX
Table 4. Weighted Decision Matrix for the clean finger function.

For the “Clean Finger” function, the embodiment with the pad attached to the removable lancet cap scored the highest.
Like the standard design currently used in practice, the pad will be encased in a sealed package; However, by
incorporating the pad into the lancet cap, we leverage material used on the upper side of the cap to form one half of the
enclosure for the alcohol pad, and we integrate the pad in a location which will be ergonomic to use and quick to apply
to the skin once the sterile barrier is broken. This concept scored consistently high compared to others in most the
criteria, with the exception of manufacturability.
4.3.2 PRICK FINGER DECISION MATRIX
Table 5. Weighted Decision Matrix for the prick finger function.

When analyzing the “prick finger” functions, it was decided that the standard lance and the torsion spring method were
the best picks for the final design. This decision lines up with our sponsors opinion that the standard lance is already
the gold standard so, if able, it would be best to use that method to draw the blood from the finger.
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4.3.3 COVER FINGER DECISION MATRIX
Table 6. Weighted Decision Matrix for the cover finger function.

After analyzing the “Cover Finger” function, the circular band-aid, large tab band-aid, and finger band-aid with string
scored the highest. These methods fit our needs the best and align with our sponsors wants. We predicted we should be
able to take these three functions as ideas and combine them into one method that offers a quick, simple, and efficient
way to cover the prick on someone's finger.
4.3.4 KEEP TOGETHER DECISION MATRIX
Table 7. Weighted Decision Matrix for the keep together function.

Analyzing shapes for the “keep together” function produced results that slightly differed from the pew matrix. The
“Rocket Ship” design preformed the highest overall weighted score, with the “semi-circle” and “thin paper” design
being very close behind. All three of these design concepts were contrasted with the best designs for the process
functions and Tim gave input on his customer perspective of each design. We concluded that the “Rocket Ship” design
was still the best design because the other functions would incorporate well into the platform, and it was well received
by Tim.
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4.4 FINAL CONCEPT DESIGN
We concluded our analysis by fusing the strongest choices dictated by our weighted decision matrix. This system design
comprises a round bandage, standard linear actuated lance, and a tear off sterilizer with pad attached on a “rocket ship”
inspired platform. This would have a prismatic device that has a lance with a safety cap, the tear-off sterilizer on the top
of the lance body, and the round bandage on the bottom of the lance body. The sterilizer and band aid can be popped
off after use of the step to expose the lancet. This also allows us to keep our subassemblies separate to aid in our FDA
strategy. The final concept prototype was 3-D printed from the Solidworks drawing, and it is shown below.
We concluded our analysis by fusing the strongest choices dictated by our weighted decision matrix. This system design
comprises a round bandage, standard linear actuated lance, and a tear off sterilizer with pad attached on a “rocket ship”
inspired platform. This would have a prismatic device that has a lance with a safety cap, the tear-off sterilizer on the top
of the lance body, and the round bandage on the bottom of the lance body. The sterilizer and band aid can be popped
off after use of the step to expose the lancet. This also allows us to keep our subassemblies separate to aid in our FDA
strategy. The final concept prototype was 3-D printed from the Solidworks drawing, and it is shown below in Figure 18.

Figure 18. 3-D printed model of the preliminary design.
4.5 PRELIMINARY DESIGN RISKS
In terms of risks to our preliminary design there are three areas of concern: complying to FDA standards, navigating
current patents, and making sure our design stays in line with our customers' wants and needs.
A significant risk for our product’s path to the market is non-compliance with FDA standards and regulations. We will
not be able to sell our product if we do not align with the FDA regulations for medical device manufacturing. We also
needed to ensure that our device fell within the Class 1 medical device category for FDA approval, so that we avoided
additional regulations which require access to resources far outside of our capability to follow through with.
Another design risk for our product is a design overlap with active patents. If our design was too similar to an existing
patent, with particular concern for our spring-loaded lancet design, our product would not be marketable for risk of
lawsuit. We had to ensure that we worked around the existing patents related to medical lancets and design our device
was novel enough to pursue a patent ourselves.
The final and most important design risk is ensuring that our product is in line with our customer base’s wants and
needs, so that the product can eventually be marketed and used widely. At the time of the conception of our
preliminary design, we had not yet received the survey results through which we confirmed our design aligned with the
customer base's needs.
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5 FINAL DESIGN
5.1 FINAL SELECTED DESIGN
The final design for our 3-in-1 Medical Lancet is shown below in Figures 19 and 20. The designs chosen started from
our decision matrices, but evolved and became based off of the analyses we conducted and the performance of our
structural prototypes. The alcohol sterilization pad (1) is adhered on the cap of the lancet, the lever arm lancing
mechanism (2) is held in the two shells of the ribbed housing, and the band aid (3) is adhered onto the back end of the
lancet with a tear-away paper covering.

1
2

3

Figure 19. Final design shown with a section view of the housing on the left and a closed overall view on the right with
the cap removed.
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Plastic cap

Low tack glue dot
Band-Aid

Trigger
Release bars
Needle Body
Top shell of housing
Bottom shell of housing
Spring
Adhesive
Paper-packaged
alcohol pad
Figure 20. Exploded view with labels for each component.
5.2 LANCING MECHANISM
Our lancing mechanism design was chosen to meet these requirements while being easy to model, test, assemble, and
manufacture. Figure 21 below shows an overview of the lance mechanism within the housing. The embodiment
displayed possesses rotating release bars.

Figure 21. Lancet mechanism overview.
Lancet mechanism components are shown below as the following: Trigger (1) – Orange, Release Bars (2) – Blue,
Needle Body (3)– Red, Spring (4) – Green. Note that the spring is shown at its natural length, while in reality, it would
be compressed to fit within the housing which contains it.
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To meet the functional requirements of the lancet, the mechanism was design with four states. Figures 22-25 show the
mechanical features of the mechanism, in each of the four states which allow the system to function as needed.
4

3
2

1

Figure 22. Lancet mechanism state 1.

In state 1, the spring is preloaded, but the trigger is at the neutral hard stop, shown in the right image with the bottom
arrow. The release bar is at its neutral state, which holds the needle body in place by the feature shown by the upper
arrow in the middle image.

Figure 23. Lancet mechanism state 2.
In state 2, the spring increases preload as the is pressed against the skin, and actuates upwards, pushing the release bars,
which in turn pushes the needle body upwards. This motion continues until the release bars open to the point that the
needle body can be pushed through, as shown by the arrow in the right image.
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Figure 24. Lancet mechanism state 3.
In state 3, the spring pushes the needle body forward to pierce the skin, after the needle body has been released through
the release bars. The needle body travels forward until hitting a hard stop, shown by the arrow in the right image, which
prevents the needle from piercing too deep into the skin. Note that the spring is past its natural length, and in the
instant shown, is providing a resistive force to the forward motion of the needle body.

Figure 25. Lancet mechanism state 4.
In state 4, the spring retracts the needle body upwards to reach its natural length, as indicated by the dotted arrow in the
right image. The needle’s sharp tip is protected within the housing and the trigger at this distance, meeting FDA
requirements for sharps control.

Figure 26. Spring attachment to the needle body, occurring with adhesive at the location of the arrow.
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This lancet design was selected as the better of our two lancet designs. The selected lancet design performed better in
our structural prototype tests, and we anticipated that this lancet design is the easiest to manufacture and test and would
function reliably. A justification of the lancet design is found in Section 5.5 of this document.
5.3 IPA SUBSYSTEM
The IPA (isopropyl alcohol) subsystem is a single use subsystem that is comprised of three components. The first is the
rear side of the lancet body which has a slightly indented surface to hold the IPA pad. This surface is secured to the
alcohol pad through an adhesive (Figure 28). The second component is the IPA pad itself, and the third component is a
paper strip which is used to seal and create packaging around the IPA. This paper strip is attached to the top of the lip
coming out of the edges of the lancet body. The paper packaging is sealed together with CA (cyanoacrylate) glue, as per
industry standard. The alcohol pad would be sealed and outsourced by a third-party vendor to comply with sterility
standards and minimize cost, though for our prototype, we adhered it by hand with an alternate adhesive, for proof of
concept.
IPA sealing

IPA Pad

Rear side of lancet body

Figure 27. IPA Subsystem with the sealing peeled away

5.4 BANDAGE SUBYSTEM
As seen below in Figure 28, The bandage subsystem has two components: a rounded-corner band aid and the cap of
the lancet. Producing the band aid would be outsourced by a vendor in mass production, to comply with sterility
standards and to obtain lower costs. The bandage will be affixed to the cap of the lancet through the use of a low tack
glue dot on the backside, similar to those shown in Figure 29. These allow the band aid to stay fixed to the cap before
use, but when stuck to the patient’s finger, the band aid can peel away from the low tack glue dot and stay adhered to
the patient. The glue dot allows for the band aid to be positioned in a convenient and quick way to use. The band aid
will be sealed with a paper covering using CA glue. The paper covering will also feature an easy-open tab similar to the
IPA subsystem.

32

Glue dot under band aid

Lancet Cap

Rounded-corner band aid

Figure 28. Bandage Subsystem

Figure 29. Glue dots

5.5 FINAL DESIGN – JUSTIFICATION
To estimate early feasibility of our designs, and to minimize the number of prototype iterations needed make the device
functional, we performed analysis on our components and the system behavior for the lancing subsystem. We examined
our worst-case loading conditions of our most at-risk component, the trigger, and began creating an unfinished model
of our spring behavior to predict the system response during use.
The first worst-case loading condition of the trigger is the bending occurring on the vertical arms when the trigger
actuates to contact and turn the lance release lever arms. The compression of the spring creates a maximum force of
1.75 lbf, which is divided between the lever arms and then is distributed to the vertical arms of the trigger. The system
was represented in our hand calculations as a fixed cantilever beam under combined loading of bending and axial
loading at the contact angle produced by the release arms at the maximum load. Our hand calculations for this loading
case (loading case 1) are included in Attachment H, and the results for these analyses are listed in Table 8. Figures 30
and 31 below display the FEA stress plot and deflection plot results.
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Figure 30. Tresca stress plot for loading case 1 on the trigger’s vertical arms. The plot shows a maximum stress of 23.7
MPa.

Figure 31. Deflection plot for loading case 1 on the trigger’s vertical arms. The plot shows a maximum deflection of
.0143 inches.
The second of the worst-case loading conditions on the trigger is the reaction occurring on the hard stops when the
trigger actuates after contacting skin, and the hard stops make contact against the internal ribbing on the lancet body.
Our estimated maximum force in this loading case was 8 lbf applied to the base of the trigger, as a worst-case use by a
user. The system was represented in our hand calculations as a beam under combined loading of bending and from the
contact force. Our hand calculations for this loading case (loading case 2) are included in Attachment H, and the results
for these analyses are listed in Table 8. Figures 32 and 33 below display the FEA stress plot and a more detailed view of
the high stress area in this study.
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Figure 32. Tresca stress plot for loading case 2 on the trigger’s hard stops. The plot shows a maximum stress of 13.2
MPa.

Figure 33. Close-up view of the stresses seen at the filleted corner of the trigger’s hard stop. A localized stress
concentration occurs at the corner, assumed attributed to mesh resolution.
Loading Case
Case 1
Case 2

Hand Calculated
Stress [MPa]
32.9
9.6

Table 8. Structural analysis summary.
FEA Maximum
FEA Maximum Deflection
Stress [MPa]
[in]
23.7
.0143
13.2
.0041

FEA Stress Safety
Factor (Tresca)
3.16
5.68

The material used in these studies was ABS plastic with a flexural strength of 75 MPa, which resulted in a sizeable
Tresca safety factor for each of the loading cases. ABS plastic is a commonly used medical grade plastic, and is a
potential material choice for manufacturing this product in the future.
A mathematical model was created in MATLAB to evaluate and tune the lance mechanism dynamics. This tool’s goal
was to derive input and output forces in the system and model the lance needle kinematics to relate the spring stiffness
and preload to the desired kinematic response. The model assumed the mechanism was a homogenous material made
of ABS plastic. The tool used a system equation of motion and state space methods to solve for the instantaneous
positions and velocities of the system. This was coupled with geometric boundary conditions and impulse momentum
dynamics to derive the tool outputs. The force required to actuate the lance and the impact force on the hard stop of
the system was found with the current design. The minimum input force was calculated at 0.211 lbf. This is an
acceptable load case since the structural analysis FEA used a load case of 1.75 lbf at the specified reaction point. The
calculated impact force of the lance at the hard stop was only 0.102 lbf, this is an acceptable design because the
structural analysis FEA performed at the point of reaction had a load case of 8 lbf. This is drastically smaller than the
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possible loads a user could put on the system coming from the opposite direction that were considered in the FEA.
Since these magnitudes are so low, there is a low risk of the mechanism demanding or creating forces that are harmful
for the device.
Table 9. Spring analysis summary.
Minimum Input Force Required for Actuation
Impact Force of Lance at Hard Stop
0.211 lbf
0.102 lbf
The kinematic modeling section of the tool has some current flaws. There are no available metrics that describe the
damping on the system with any reliability. Since there is no reliable input, the system has no damping which produces
a harmonic oscillation as the dynamic output. This is a very unrealistic output in practice. To fix the model we would
perform low fidelity testing to determine a rough damping coefficient through log decrement methods. Once the scale
spring and SLA housing are obtained, these tests can be performed. The model would then be tuned by iterating the
springs stiffness and preload. Our specified design has been made easy to tune, with the chosen spring having a variety
of options at the same size and different stiffness rates from our supplier. This would require very little design changes
to tune the system for a desired response. We are aiming for an underdamped response or similar with the overshoot
occupying the finger prick motion. This specific lance motion important to maintain compliance with sharps control of
the single use product.

Figure 34. Lance needle response as determined by inaccurate MATLAB analysis. Future testing and tuning are
necessary to produce a realistic dynamic model.
5.6 STRUCTURAL PROTOTYPING
Our team created several structural prototypes to iterate through different designs and to conduct early feasibility
testing of our ideas. The prototypes were instrumental in allowing us to converge on a successful design which met the
criteria we sought out to fulfill. The most significant of our prototypes were 1. Scaled up FDM prints of mechanisms
and snap fits, 2. Initial SLA print of full assembly, and 3. Final/altered subsystems designs SLA prints.
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5.6.1 STRUCTURAL PROTOTYPE 1
The initial, scaled-up structural prototypes of our 3-in-1 medical lancet were of two different housing designs and
lancing mechanisms. Both were 3D printed and scaled +2.5x in size to make testing and troubleshooting easier, since
our final device dimensions are so small. The housing was tested for how the snap fit works between the top and
bottom half of the design, and if it would stay intact while someone is using it and applying force on it. The punching
mechanism also was tested separately to work out how the actual act of punching works, and to see if it works with
reasonable constraints (i.e., force applied to release needle, the needle retracting back into the body, etc.).
An important consideration for our structural prototype was the printability of the design, while keeping in mind that
our end goal is to eventually to injection mold the components. The housing on the lancet was made with ribbing
throughout the body to ensure stability and give a path for the punching mechanism to follow, and to represent how
the molded component would be made.
Two structural prototypes were made, one following each design path. The first one, shown in Figure 35, is the lancing
mechanism described in the above sections, printed at 2 times scale using PLA (polylactic acid) 3D printing. We chose
to move forward with this design because of its ease of printing, while also being the more reliable mechanism.

Figure 35. 3D printed model of the housing with lancing mechanism.
The second structural prototype, the “Deflection Design” is shown in Figure 36 below. It was also printed using PLA,
at 2.5 times scale. We chose to not proceed with this design direction because the lancing mechanism, although using
less parts, was not reliable in performing its function. However, the annular snap fits, which use hoop-strain to hold the
two pieces together, were integrated into our final design. When snapping each of the models together, this model
snapped the snuggest and proved to withstand our simulated use.

Figure 36. 3D printed CAD model of the alternative design.
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5.6.2 STRUCTURAL PROTOTYPE 2
Our second structural prototype was made on an SLA printer, which allowed us to improve the resolution, layer
homogeneity, and surface finish of the parts. We were able to print at a 1x scale for the first time with this resolution
and tested the device’s functionality for the trigger mechanism and the ease of use and ergonomics for all subsystems.
The SLA resin we used was what was available on campus, which had similar properties to a typical medical grade
plastic (slightly weaker and less stiff than ABS, but comparable).

Figure 37. Second structural prototype of the lancet mechanism, at 1x scale in SLA resin material.

Figure 38: Old cap design
5.6.3 STRUCTURAL PROTOTYPE 3
Our final prototype was another iteration of the SLA print with new designs for our bandage and IPA subsystems, and
was the device used for our design verification testing. We determined that the new subsystem designs performed better
than those used in our second structural prototype, and so we established them as a part of our final design. The new
designs consisted of our IPA subsystem moving to the bottom of the housing, and the band aid being attached to the
cap which is removed off the trigger, with ergonomic shape features added to the cap in order to ease the band aid
application, and to integrate a ¼ turn release for the cap to prevent accidental uncapping which was experienced in the
second prototype.
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5.7 COST ANALYSIS

Figure 39: New cap design

At the end of our prototype and design process, the cost to create our prototype is still fairly low compared to our
budget, but the price per unit device is high relative to the summation of the costs for all the materials required to carry
out the current process. This is due to the fact that our prototyping was very low volume production compared to the
units made in industry.
For the 3D printing used in our prototype design, we were able to utilize the free printing resources on campus. Noncustom parts such as the spring, needle, IPA and bandage took money out of our budget, and the costs associated with
these can be found in Appendix G in the indented bill of materials. At the time of this document’s publishing, we have
currently spent $28.03 on materials that have gone into our final design prototypes. A full listing of these items is found
below.
Table 10. Summary of final prototype costs
ITEM(s)
Spring (variety pack)
IPA Pads (100ct)
Adhesive (50mL)
Glue dots (200ct)
Bandages (50ct)
TOTAL

COST
$8.99
$6.59
$3.21
$7.00
$2.24
$28.03

As the product is developed further, it will inevitably be moved to mass production. Injection molding manufacturing
processes for the custom components will be implemented to mass produce parts. Because injection molding requires a
high up-front cost, but can produce a great volume of components for very cheap, it will overall be a much better
investment than attempting to 3D print the design at mass scale. We also expect the production and assembly of the
bandage and IPA subsystems to be done at high volume. Because the cost of these extraneous components should be
relatively constant, the price per unit should be steady as a whole, and we predict results outlined in Table 10 below.
The cost estimate assumes a production scale of (likely over 100,000) units molded in low-cost, medical grade plastic.
Note that our estimate does not include the sterilization of the system, which is difficult for us to determine without
any quoting from a vendor, which is yet to be completed.
Table 11. Estimated per-unit costs in mass production
ITEM
Injection Molded Components
Band Aid System
IPA System
Spring
Adhesives
TOTAL

COST PER UNIT
$0.15
$0.06
$0.08
$0.08
$0.05
$0.42
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5.8 SAFETY, MAINTENANCE & REPAIR
Safety is a major concern for this project, especially as we are dealing with a medical device that will be used in
emergency situations. However, the one-time usability of our device simplifies the safety, maintenance and repair
outlook of our device. The full FMEA (Failure Mode & Effects Analysis) can be found in Appendix E, where potential
failure cases are addressed.
In our Hazards Checklist, found in Appendix D, two areas of hazard were addressed. First, the needle of the lancet is a
sharps hazard. This hazard has been accounted for throughout our design process. The needle will only be exposed at
the time of contact, as the trigger mechanism covers up the needle in its post use state. The other hazard that was
addressed was the product being used in an unsafe manner. The product is designed in a way that makes accidental, or
malicious use very unlikely and very harmless, the design of the lance can be found in Section 5.2. The needle is covered
up by a lancet cap that requires intentional use, and the punch mechanism is designed so that an accidental trigger is
highly unlikely. Further, the needle only protrudes about 0.05 inches, making an accidental or malicious puncture
innocuous. Both of these hazards are also addressed in our Design Verification Plan (Appendix F), where sharps
control is tested on the device.
In terms of the maintenance and repair of our project, it is designed to be a one-time use device, so the device will not
need maintenance or repair.
5.9 REMAINING CONCERNS
The accuracy of 3D printing is not exactly within the parameters necessary for our design, but during the development
of our design, we were able to use this process to get a broad idea of our product. 3D printing is affordable and has a
quick lead time, so it was a good option to use for prototyping. To ramp towards high production, once we lock in a
design we are confident with, the switch over to injection molding will be made, which will give us tighter tolerances,
better surface finishes and material properties, and far lower costs at high volumes. However, this will require more
analysis to determine if any structural changes are necessary.
Another concern we have is the ability to eventually manufacture the IPA and bandage components in a sterile, lowcost manner. Eventually a custom parts manufacturer that can comply with our sterility standards and small sizes will
need to be found.
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6 MANUFACTURING
The 3 in 1 Medical Lancet prototype consists mainly of custom 3D printed components, with other outsourced
components that are modified/assembled by hand. The lancet body, internal parts, and cap were 3D printed and
assembled (with a spring) to make the lancing mechanism. The remaining bandage and sanitizing subsystems were
initially outsourced and then modified to work with our design.
6.1 PROCUREMENT
The components that were not 3D printed were all purchased from third party medical manufacturers. These
components include: the lancet needle (Care Touch), the lancet spring (McMaster Carr), the bandage (Johnson &
Johnson), and IPA (Med Pride) (as well as their respective seals), and the adhesives to affix the bandage and IPA to the
body of the product (Uline).
Our team was fortunate enough to receive two grants: the CP Connect grant and the funds from the mechanical
engineering department. These funds were used to procure all the materials that went into our product, as well as
materials for the subsequent tests that were carried out on our device. At the time of this writing, our team has $753.37
left in funds and we have spent a total of $396.30 so far on this project.
6.2 MANUFACTURING
The primary manufacturing method used to create our prototype was stereolithography (SLA) 3D printing. Aside from
the spring, lancet needle, IPA, and bandage subsystems, all components of the lancet were 3D printed. The full step by
step outline of the manufacturing of our device can be found in Appendix O in the Manufacturing Plan summary table.
Our team, assisted by Eric Pulse, printed our verification prototype and consecutive revision models using a Formlabs
Form 3 SLA 3D printer. The parts were printed using photopolymer resin manufactured by Formlabs. After printing
the parts were postprocessed. The first step of postprocessing is immersion in a 98% IPA bath which removes
unwanted, uncured resin. The second step involves moving the prints from the IPA bath to a UV light station to finish
curing the resin to improve strength and finish. The third postprocessing step is to remove printing supports with wire
end cutters until only the desired part geometry is present. The last postprocessing step is to sand bumps and edges
where the support material was clipped with fine 300 grit sandpaper. By following these steps, we can achieve small and
accurate features without the large investment of injection molding prototype tooling. The printer and the post
processing stations are shown below in Figure 39. On the left is the 3D printer, the middle is the IPA bath, and on the
right is the UV light curing station.

Figure 40. Formlabs Form 3 printer and post processing stations.
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The lance needle part was modified after being printed to add the metal needle. This was done by drilling a hole axially
down the front of the plastic part with a #60 drill bit. The metal needle was then inserted in the hole and backfilled
with superglue to adhere it in place. The metal needle was harvested from a plastic encased lance needle procured
earlier. The two remaining components of our device, the band aid and IPA sub-assemblies, do not involve 3D
printing, the components were procured from medical manufacturers and easily assembled using scissors and adhesives.
6.3 ASSEMBLY
The main mechanism keeping the lancet internals in place is the housing snap fit, providing ease of manufacturing and
quick assembly. The lancing mechanism components are placed into the bottom shell and the top shell fits over these
components, snapping into place to enclose them. The protective cap attaches and prevents the lancet from being
triggered by accident. The bandage attaches to the cap via glue dots, and the IPA pad attaches to the bottom of the
lancet body, sealed by a custom cover. A step-by-step procedure of each assembly is outlined below.
Main Assembly w/ Lance Mechanism
1. Insert the trigger housed inside the back shell pressed down against the bottom of the housing.
2. Insert the release arms into their pivot points flat against the trigger arms.
3. Load the lance body into the center channel of the housing by compressing the spring and resting the front
protrusion of the lance body against the release arms.
4. Tuck the top coil of the spring into the slot in the housing.
5. Snap front shell onto back shell.

Figure 41. Assembled lancet prototype interior components.
Alcohol Prep
To assemble the alcohol prep pad, first the IPA needs to be removed from the original packaging and then cut into a
0.7” x 0.3” rectangle. Then, this is affixed to the backside of the lancet body with the permanent adhesive. Lastly, the
paper covering/tab is put over the IPA and adhered to the device with polyvinyl alcohol adhesive (PVA adhesive glue).
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Figure 42. IPA prototype subsystem.
Bandage
1. Place two high tack glue dots onto the indented area on the cap of the lancet.
2. Place a low tack glue dot on top of each of the high tack glue dots.
3. Unwrap a 1-inch by 1-inch square band aid and place onto the glue dots on the cap.
4. Press down firmly to ensure the band aid adheres to the glue dots.
5. Glue sterile paper covering over bandage with polyvinyl alcohol adhesive (PVA adhesive glue).

Figure 43. Bandage prototype subsystem.
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6.4 CHALLENGES
The main challenge that our team faced during the manufacturing stage was finding quality, timely resources on campus
to 3D print with. There was confusion within the mechanical engineering department as to where the SLA printers
were located, causing our printing process to be delayed. Once we located the SLA printer, printing was high quality
and quick when we needed to print subsequent revisions.
Another manufacturing challenge our team faced was interfacing the band aid with the lancet device. The band aid is
pressed onto patient’s finger and needs to release from the lancet body when it has adhered to the patient’s skin. Our
team’s solution involved combining two adhesives with different tack levels so that the band aid would release at the
correct time. Further, this is a problem that we believe is easily solved in future production with more resources.
6.5 FUTURE PRODUCTION
In future production contexts where this product was being brought to market, our manufacturing processes would
have to change to scale to large-scale manufacturing and comply with FDA sterility requirements. First, to scale the
lancet production our plastic pieces would have to be injection molded using a medical grade plastic. Injection molding
tooling presents a large investment up front but would be the best method to create the product at the lowest price per
unit, since it is single use and therefore very high production rates would be required. The injection molding process
would likely be outsourced to a 3rd party medical-product manufacturer that has a focus in injection molded medical
devices.
The other manufacturing changes are to ensure sterility of the product and pass FDA validation. First, the needle would
be over molded in injection-molded plastic after being sterilized. This over mold could include a piece that connects the
end of the lance to the end of the cap which breaks when the cap is removed, exposing the sterile needle. The next
manufacturing change would be to work with a band aid manufacturer to make a large-scale order of band-aids that fit
within our design dimensions. This ensures that a company with experience making seals will maintain sterility
standards and hold some liability since we are the customer. The last manufacturing change would be to order a custom
sized alcohol wipe that is small enough to fit our device in a bulk order. We would then have to glue the outsourced
alcohol wipe and band aid to the desired surfaces with adhesive. By outsourcing our band aid and alcohol production
we can also ensure we maintain compliance with our device classification as a “kit” which allows us to classify as a class
1 and have a far easier validation process.
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7 DESIGN VERIFICATION
7.1 DESIGN VERIFICATION PLAN
The design verification plan outlines the details of how each specification laid out in the QFD House of Quality will be
tested. The plan outlines the criteria being tested, the equipment that was used in each test, and which team member is
taking the lead for each test. The complete design verification plan can be found in Appendix F: Design Verification
Plan. A short description of the tested criteria are listed below.
7.1.1 SHARPS CONTROL
Sharps control, or the ability of the device to keep users safe from sharp objects (the lancing needle), is a big FDA
consideration, and the device need to keep the lancet needle protected when not in use. This test is pass/fail, based on
if the product keeps sharps control.
7.1.2 TIME TO COMPLETE PROCESS
As per the purpose of the product, the time the user takes to complete the blood glucose test shows whether the device
successfully accomplishes our main design goal. Once the prototype was completed, it was used in a simulated-use case
for the full process. The goal was to complete the process in under a minute.
7.1.3 SUCCESS RATE OF PRICK
Standard blood lancets, according to our survey answered by over 50 EMTs, are successful in drawing blood 9/10 times
on average. So, in order to compete with the existing process, we stated our product must draw blood at a success rate
of at least 90%. This test used a piece of synthetic skin which the lancet was deployed on, and was a pass/fail test based
on if it penetrated the skin.
7.1.4 FORCE REQUIRED TO DEPLOY LANCET
In order for the product to be user friendly, the lancet deployment should not require excessive force. We targeted a
force of 0.211 lbf as the predicted force to engage the lancing mechanism. This test would determine our lancing
mechanism’s required force to deploy.
7.2 DESIGN VERIFICATION PROTOTYPE
The design verification prototype represents what the final design of the 3-in-1 medical lancet would look like and was
used to complete all of our testing. The main differences the prototype has from our final design are in the band aid
and IPA subsystems, because we were unable to seal them in the way a real production environment would. However,
we attached the systems in a way to represent the forms they would take in the final design, and they were usable
enough to simulate the full use of the device for our testing.

Figure 44. The final design for the design verification prototype.
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7.3 TEST PROCEDURES
We verified our design specifications by accomplishing 4 different tests. The first was a prick success rate test. This test
involved pricking synthetic skin to make sure the lance worked as needed. The second test was a timed usage test. This
test determined the time to complete the entire procedure using our device compared to the time it takes to use the
traditional device. This test was one of the most important because it tells us how well our design satisfies the need
from our user. The third test was a lance displacement test that ensures the hard stop on the lance works as intended to
not overextend. The last test was a force input test to make sure the trigger mechanism is not too sensitive or too stiff
for users.
Table 12: Engineering Specification Verification Breakdown
Spec #

Requirement or
Target (units)
Meets protocol
for pathogen
presences (ppm)

Tolerance

1

Specification
Description
Sterility

Y/N

Verified?
(Y / N)
Y*

2

Time of use

25 (seconds)

Max

Y

3

Number of
Steps

4 (steps)

Max

Y

4

Cost/unit

2.00 ($)

Max

Y

5

Size

3 (in3)

Max

Y

6

Blood Draw
Efficacy
Packing
Efficiency
(Amount fit in
glucometer
bag)
Sharps
Control

90 (%)

Min

Y

6 (devices)

Min

Y

Satisfies FDA
regulations

Y/N

Y*

7

8

9

Input force to
deploy lancet

<1 (lbf)

Max

Y*

10

Learning curve
/ Intuitive use

Learn in 30 (s)

Max

Y

11

Meets user
goals w/
survey

Meets goals

Y/N

Y

Verification Description
Production design sterilized and over
molded to cap. Prototype does not need
to be sterile as there are no human use
cases.
23.53 seconds average time of use per
timed use test
3 steps as defined in design and
demonstrated in timed use test. (When
using as intended there as only 3 steps
accomplished.)
($1.41/resin parts) + ($0.05/band aid) +
($0.02/alcohol wipe) + ($0.04/needle) +
($0.05/spring) = $1.57
Volume of bounding box (a rectangular
prism that would fit the device at its
largest dimensions) is only 1.65 in^3.
100% efficacy from puncture test in
synthetic skin.
The verification prototype is not much
larger than a single lance, which fits over 6
in a single glucometer bag.
Needle retracts into plastic body to isolate
sharp from the outside environment per
FDA precedence. The lance body can be
thrown away immediately after
deployment which satisfies operational
procedure for EMTs.
Could not obtain reliable force input but
user feedback shows the lance “felt” the
same when pushing in for deployment as
other lances on the market, which satisfies
specification intent.
We told Tim how to use the device in
under 30s and he understood how to use it
and could run through the process.
Users primarily wanted to save time and
our timed test led to a 70% improvement.
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*Indicates conditional verification. A verification that is not important or possible for the prototype but is dependent
on production level manufacturing processes and techniques.
7.3.0 TESTING HAZARDS
One of our tests, the prick success rate test, involved live needles. The hazard of the needle was dealt with according to
the senior project FMEA and Hazard procedures. The hazards and their respective corrective actions are outlined in the
table below:
Table 13. Hazards and corresponding corrective actions

7.3.1 PRICK SUCCESS RATE TEST
The purpose of this test was to verify the success rate of the needle prick in the lancet subsystem. We tested this by
firing the device onto synthetic skin. Figure 39 below shows how we fired the lancet on the right and the recording of
each test on the left.

Figure 45. Prick Success Rate Testing.
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For this test, a live needle was used in the lancet body so that we could test the true functionality. The synthetic skin
was the best indicator of whether the system could produce the forces necessary in order to drive the needle forwards
enough to sample blood on a patient. The synthetic skin was examined after the test in order to verify that the needle
had in fact punctured at the site we aimed for. New test sites were used for each test. Due to the lack of supply of
needles we had, we used the same needle for each test. Thankfully, we did not notice a significant amount of dulling
from the synthetic skin.
Our design had a perfect score on our prick success rate test - the lance subsystem successfully fired every time,
piercing the synthetic skin with a success rate of 100%. This surpasses the benchmark of 90% success rate that the
current process has and verifies that our lance subsystem is a reliable lancing method.
7.3.2 TIME OF USE TEST
The purpose of this test was to ensure that the device accomplishes its purpose in a short amount of time to provide
maximum ease of use. This test encompasses every element of the product as it goes through each step of the process.
The criteria were tested 10 times, ensuring that an accurate result is obtained. The average time to complete the process
was expected to be under 60 seconds, to compete with the existing blood glucose monitoring process. A time under 40
seconds is desirable to compete with the results from the survey we sent out to paramedics and nurses.
The average time from the ten tests was 23.52 ± 1.30 seconds. This verified that our design is an improvement over the
current process by a margin of 41.8%. This is a key metric in proving that our design is successful.
We performed an uncertainty analysis for the time of use test because the results are numerical data, and this test is very
important in evaluating how much we improve from the existing process. A total uncertainty was determined by
considering measurement resolution uncertainty and statistical uncertainty. The measurement resolution had little
weight on the total uncertainty, with statistical uncertainty driving the majority of the total. Statistical uncertainty was
determined by analyzing the 10 data points for a 95% confidence interval. This led to a total uncertainty of ± 1.30
seconds for our time output. Therefore, there is a possible ±5.5% variation in our determined average, which is still
under our specification goal and a significant improvement from the preexisting process.

Figure 46. Uncertainty Analysis Equations. The full analysis is available in Appendix K.
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7.3.3 NEEDLE DEPLOYMENT DISTANCE TEST
The purpose of this test was to reassure that the lancing mechanism is working and deploying the needle at a significant
distance to puncture the skin on a patient’s fingertip.
The needle deployment distance was measured with the test fixture shown in Figure 40. There are etchings marking
each millimeter. A tripod held an iPhone filming in slow motion as the lancet was pressed against the fixture until the
needle deployed. Then, the measurement was read from close visual examination of the video for the maximum
displacement.

Figure 47. Testing of Deployment Distance
The deployment distance test verified that our lancing mechanism worked as it should. Our design deployed an average
distance of 1.05 mm which meets our design requirement of deploying between 1 and 1.5 millimeters.
7.3.4 INPUT FORCE TEST
The purpose of this test was to verify that the input force to deploy the lancet is comparable to lancet products
currently on the market. This input force is to compare the user feel of pushing it in and make sure it deploys similarly
to currently available options on the market.
At the time of this submittal this test was not able to be completed, due to not being able to find a faculty member who
could assist in setting up the load cell. We are currently reevaluating and will either use a scale or a cell from a different
lab. We feel that this is the least important test, as even without the load cell verification, the lancet is very easy to
trigger based on feedback from users so far and is not noticeably different in comparison to current products. Since this
test aimed to quantify a qualifiable specification, we find it sufficient to consider the user feedback feeling similar to
current lances as a satisfactory outcome. While we can not quantify the input response at this time, we can still say our
specification is conditionally verified since it appears we will pass our specification since we achieved our desired core
outcome.

49

8 PROJECT MANAGEMENT
This project was completed over the course of three ten-week quarters, starting in January 2021 and culminating in the
publishing of this document in December 2021. Table 3 displays a timeline of the deliverables that were due, starting
with a Scope of Work and culminating in the publishing of this document. Throughout the project, we kept track of
our deliverables and scheduling using a Gantt chart. A visual representation of this project schedule can be found in
Appendix B.
Table 14. Key Deliverables
Deliverable
Scope of Work
Preliminary Design Review
Interim Design Review
Critical Design Review
Final Design Review

Due Date
February 4, 2021
March 4, 2021
April 8, 2021
May 6, 2021
December 2, 2021

8.1 PROJECT BUDGET
Our team received funds from both the mechanical senior project grant ($500) and the CP Connect grant ($600). These
funds were used to purchase materials needed for the development and manufacturing of our final design. We
anticipated needing these funds mostly for the 3D printing of our prototypes. However, we were able to print cost free
through Mustang 60, and thus did not use the majority of our budget. Our budget, and the purchases made with the
funds, can be seen below in Appendix N.
Table 15: Funds available at beginning of project
Grant
Amount ($)
CP Connect
650
Senior Project Grant
500
Total
$1150
Table 16: Purchases made and remaining funds
Description
Date
Amount ($)
Band aids, springs, glue, sandpaper
April 15, 2021
45.79
Synthetic skin, springs, adhesives
May 31, 2021
350.51
Remaining Funds
$753.70
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9 CONCLUSION
This report outlined the design process our team has undertaken for the past three quarters. It describes the design
ideation, analysis, prototyping/manufacturing, management, and logistics, as well as the future direction for our
product. The entire process was extremely valuable and rewarding despite the many times we struggled and got
frustrated. Finding faults in your design is a part of the engineering design process, and as frustrating as it might be,
lends to the final prototype turning out the best version it can be.
Our verification prototype manufacturing process was relatively simple, focusing on 3D printed components with post
processing, a few modifications, and final touch ups afterwards. This method still taught us all a lot about designing
with a manufacturing mindset. We went through several different types of 3D printing and pushed the limits of our
manufacturing resources until we found satisfactory results in the SLA printing. This involved talking to different
professors and working with shop techs to figure out how to get the best prototype possible. We also designed our
verification prototype knowing the next level of manufacturing would require scaling to injection molded tooling. This
long-term goal was a primary driver of designing printed parts for most components since in scaled production those
parts would also be plastic.
We have come a long way in the 9 months we have spent working on this project. It is satisfying and exciting to have
made a product that works and meets the expectations and specifications we set at the beginning of the year. The next
step in the design process would be to iterate the design to be mass produced. This involves contacting injection
molding manufactures and making subtle updates to the CAD model and detailed design drawings to aid in design for
manufacturability (DFM). We would also need to find band aid and IPA manufactures to contract custom sizes that
would interface with our model well and meet sanitation specifications for the FDA.
While the next design steps are focused on scaling and very long-term goals, the immediate next step of this project is
to share the product idea to get support in scaling and realizing the product. This project, while providing a developed
design solution, gives our sponsor a well thought out product design with supporting visuals and analysis that are
valuable in finding funding, securing patents, and communicating the design idea to others. Our design research allowed
us to incorporate key strategies and subtle workarounds into our design that will simplify the FDA validation process
and possibly save millions in development testing and validation procedures. This next step in the project will greatly
benefit from those initial research explorations. This project provides a jumping off point for our sponsor to have
supporting material in realizing this vision and hopefully, get our product in the hands of first responders. This
document will be reviewed by our sponsor, Tim Nurge, who will decide the extent he wishes to continue this project.
In short, this project gave Tim Nurge a physical functioning prototype of the product he had in mind. The prototype
will give Tim the basis to develop the product further, or to present the idea to seek investment or purchase.
Regardless, we all hope someday this valuable process improvement can find its way into the hands of those who need
it most.
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APPENDIX D
Design Hazard Checklist
Y

N
x

1. Will any part of the design create hazardous revolving, reciprocating, running, shearing, punching,
pressing, squeezing, drawing, cutting, rolling, mixing or similar action, including pinch points and sheer
points?

x

2. Can any part of the design undergo high accelerations/decelerations?

x

3. Will the system have any large moving masses or large forces?

x

4. Will the system produce a projectile?

x

5. Would it be possible for the system to fall under gravity creating injury?

x

6. Will a user be exposed to overhanging weights as part of the design?

y

7. Will the system have any sharp edges?
x

8. Will any part of the electrical systems not be grounded?

x

9. Will there be any large batteries or electrical voltage in the system above 40 V?

x

10. Will there be any stored energy in the system such as batteries, flywheels, hanging weights or
pressurized fluids?

x

11. Will there be any explosive or flammable liquids, gases, or dust fuel as part of the system?

x

12. Will the user of the design be required to exert any abnormal effort or physical posture during the use of
the design?

x

13. Will there be any materials known to be hazardous to humans involved in either the design or the
manufacturing of the design?

x

14. Can the system generate high levels of noise?

x

15. Will the device/system be exposed to extreme environmental conditions such as fog, humidity, cold,
high temperatures, etc?

x

16. Is it possible for the system to be used in an unsafe manner?
x

17. Will there be any other potential hazards not listed above? If yes, please explain on reverse.

Description of Hazard

Planned Corrective Action

The lancet will be sharp, designed to
puncture human skin

Because the lancet is planned to use the current process, which
involves a needle that is only exposed during the time of contact,
this hazard is already accounted for

The lancet could potentially be used in an
unsafe manner

Unless the lancet is purposefully used to puncture someone in an
unsafe manner, it is highly unlikely to be used unsafely
accidentally. The punch design keeps the risk of accidental needle
deployment low.

59

APPENDIX E
FMEA
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APPENDIX F
Design Verification Plan
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APPENDIX G
Indented Bill of Materials
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APPENDIX H
Hand Calculations for structural analysis of the trigger component
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APPENDIX I
MATLAB code for the spring model
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APPENDIX J
Drawing Package
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APPENDIX K
Uncertainty Calculations
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APPENDIX L
Tabulated Test Results
Table 1. Deployment Distance Test Procedure
Test #

Fired
successfully?
(Y/N)
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Distance
Distance
acceptable(Y/N) (mm)
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.5
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.5
1.0
1.0
1.0
1.0

Table 2. Prick Success Rate Results
Test #
1
2
3
4
5
6
7
8
9
10

Successfully fired? (Y/N)
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
79

Table 3. Time of Use Results
Test #
1
2
3
4
5
6
7
8
9
10
Average

Time (s)
25.5
22.2
21.5
26.3
23.2
24.5
22.6
23.4
25.6
20.5
23.53
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User Manual
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Tabulated Purchases
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